Nektar Therapeutics (NKTR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

NKTR Nektar Therapeutics

Watchlist

1.0500
+0.0400+3.96%

Close Nov 22 16:00 ET

1.0999
+0.0499+4.75%

Post 20:01 ET

193.68MMarket Cap-1250P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

B-cell Lymphoma Pipeline Insight 2024, With Comprehensive Insights for 295+ Companies and 300+ Pipeline Drugs - ResearchAndMarkets.com
BusinesswireNov 22 12:14 ET
Insider Sale: Chief R&D Officer of $NKTR (NKTR) Sells 7,785 Shares
Quiver QuantitativeNov 20 20:45 ET
Nektar Therapeutics Presents First Preclinical Data From Novel CSF-1 Program, NKTR-422, At 2024 American College Of Rheumatology Convergence; NKTR-422 Demonstrated Inflammation Resolution And Tissue Repair In Multiple Preclinical Models Of Chronic...
BenzingaNov 18 15:32 ET
Getting In Cheap On Nektar Therapeutics (NASDAQ:NKTR) Is Unlikely
Simply Wall StNov 18 10:10 ET
Nektar Therapeutics Presents First Preclinical Data From Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
NektarNov 18 00:00 ET
Nektar Therapeutics To Present At UBS Global Healthcare Conference; Webcast At 1:15 PM ET
RTTNewsNov 13 12:18 ET

Comments

Jaguar8

Nov 18 14:56

NEWS

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
Nektar Therapeutics (NKTR) presented preclinical data for NKTR-422, a novel modified CSF protein, at the 2024 ACR conference. The drug demonstrated promising results in inflammation resolution and tissue repair across multiple preclinical models. NKTR-422functions by targeting anti-inflammatory tissue resident macrop...

Teddy123

Nov 8 17:20

Nektar Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(8.7%)

$Nektar Therapeutics (NKTR.US)$
Target price $7

Teddy123

Nov 4 09:04

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

$Nektar Therapeutics (NKTR.US)$
SAN FRANCISCO, Nov. 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and...